Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

Novo files for EU approval of Tresiba/ Victoza combination in diabetes

Ideglira combines insulin degludec and GLP-1 analogue

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

Novo Nordisk on track to file liraglutide in obesity

Expects regulatory filings in the US and EU by the beginning of 2014

- PMLiVE

J&J expects to file 10 new pharma products by 2017

Healthcare company also expects 25 significant brand-line extensions

- PMLiVE

VCCP Health wins Mundipharma’s new product launch business

Agency hired to drive new product launches across Europe

- PMLiVE

Roche repeats cancer drugs warning as Avastin faces another NICE rejection

Concerns about future of Cancer Drugs Fund

- PMLiVE

France ignores EMA and suspends Bayer’s Diane 35

National Agency for the Safety of Drugs and Health Products contradicts PRAC verdict

Bayer symbol

EMA says Bayer’s Diane 35 should remain on European market

Agency investigation concludes acne treatment's benefits outweigh its risks

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links